Health Care Reform Licensing Prescription Drug Pricing 
Kaiser Health News
MARCH 15, 2023
“We had a massive opioid problem that needed to be rectified,” said Antonio Ciaccia, president of 3 Axis Advisors , a consulting firm that analyzes prescription drug pricing. “But the federal crackdowns and guidelines have created collateral damage: patients left high and dry.”
Kaiser Health News
MARCH 15, 2023
“We had a massive opioid problem that needed to be rectified,” said Antonio Ciaccia, president of 3 Axis Advisors , a consulting firm that analyzes prescription drug pricing. “But the federal crackdowns and guidelines have created collateral damage: patients left high and dry.”
Hall Render
MAY 10, 2024
Health Policy Commission still missing key document in Steward sale to Optum Local obesity drug developer lands deal worth up to $600M with Novo Nordisk Mass.
Expert insights. Personalized for you.
96 
Let's personalize your content